Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Alan Harsch

Pediatric Pulmonology Concord, NC Medical Doctor

NPI 1912948795 CMS profile 313351

100 Medical Park Dr, Ste 310, Concord, NC 28025

Open in the dashboard

General payments

$1,711

44 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Harsch of Concord, NC is reported in the CMS Open Payments database as having received $1,711 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Pediatric Pulmonology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $416 13
2024 General $538 14
2023 General $519 12
2022 General $238 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Harsch
  • Pediatric Pulmonology median
  • Middle half of Pediatric Pulmonology
  • National median

In program year 2025, general payments to Alan Harsch were reported at $416. Among 622 Pediatric Pulmonology profiles paid that year, the median was $139 and the middle half received between $60 and $405.

Show as a table
Year Alan Harsch Pediatric Pulmonology median Middle half National median
2019 $0 $151 $59–$495 $163
2020 $0 $107 $34–$339 $114
2021 $0 $125 $40–$511 $132
2022 $238 $133 $49–$428 $149
2023 $519 $138 $44–$494 $160
2024 $538 $132 $46–$398 $164
2025 $416 $139 $60–$405 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $499 5 payments
  2. Regeneron Healthcare Solutions, Inc. $297 7 payments
  3. Pharming Healthcare, Inc. $278 9 payments
  4. Amgen Inc. $262 10 payments
  5. Genzyme Corporation $117 3 payments
  6. Baxter Healthcare $104 5 payments
  7. Sanofi-Aventis U.S. LLC $75 1 payment
  8. Philips Electronics North America Corporation $42 2 payments
  9. Electromed, Inc. $20 1 payment
  10. Actelion Pharmaceuticals US, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,637 43 payments
  2. Education $75 1 payment
Products named General payments · program years 2022–2025
  1. TEZSPIRE Respiratory $499 5 payments
  2. TEZSPIRE Inflammation $262 10 payments
  3. DUPIXENT Inflammation And Immunology $241 5 payments
  4. DUPIXENT Immunology $192 4 payments
  5. RUCONEST $161 8 payments
  6. JOENJA $117 1 payment
  7. Hillrom - Vest System Model 105 Home Care $67 3 payments
  8. DUPIXENT Immunology And Inflammation $57 2 payments
  9. (AK6) Vest Therapy $23 1 payment
  10. SMARTVEST $20 1 payment
  11. Other $56 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Pulmonology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record